Trials / Terminated
TerminatedNCT01884129
Prognostic Value of CTC in HNSCC Patients
Prognostic Value of Circulating Tumor Cells in Patients With Locally Advanced and Metastatic/Recurrent Head and Neck Cancer
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 53 (actual)
- Sponsor
- Chang Gung Memorial Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.
Detailed description
1. Histologically or cytopathologically proven head and neck squamous cell carcinoma (HNSCC) 2. Disease status: locally advanced or recurrent/metastasized at initial presentation 3. Age \>=20 years old 4. Could understand and signed the informed consents of this study 5. Enrolled patients were classified into three distinct subgroups: 1. Patients underwent curative surgery followed by adjuvant chemoradiotherapy (CRT) because of some pathologic features such as positive margin, pathologic N2, and extracapsular spread (ECS) of involved lymph nodes indicating early relapse according to recommendation from National Comprehensive Cancer Network(NCCN) guidelines; 2. Patients with advanced disease directly underwent definitive concurrent chemoradiotherapy(CCRT); 3. Patients were to have palliative chemotherapy for existence of distant metastasis or poor general condition for definitive CCRT. 6. Blood samples were collected within 7 days before the first dose of chemotherapy.
Conditions
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2013-06-21
- Last updated
- 2015-12-10
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01884129. Inclusion in this directory is not an endorsement.